$XGN
Exagen Inc

2021 Q4 Form 10-K Financial Statement

#000162828022006926 Filed on March 22, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $12.69M $48.30M $12.67M
YoY Change 0.15% 15.07% 24.09%
Cost Of Revenue $4.939M $20.59M $4.340M
YoY Change 13.8% 24.33% -5.45%
Gross Profit $7.750M $27.71M $8.330M
YoY Change -6.96% 9.03% 48.22%
Gross Profit Margin 61.08% 57.37% 65.75%
Selling, General & Admin $11.80M $44.54M $9.930M
YoY Change 18.85% 20.27% 25.38%
% of Gross Profit 152.28% 160.73% 119.21%
Research & Development $2.202M $7.237M $1.170M
YoY Change 88.21% 102.83% 105.26%
% of Gross Profit 28.41% 26.12% 14.05%
Depreciation & Amortization $292.0K $900.0K $160.0K
YoY Change 82.5% 80.0% 45.45%
% of Gross Profit 3.77% 3.25% 1.92%
Operating Expenses $14.00M $51.78M $11.09M
YoY Change 26.28% 27.53% 30.78%
Operating Profit -$6.254M -$24.07M -$2.760M
YoY Change 126.59% 58.49% -3.5%
Interest Expense -$639.0K $2.625M -$650.0K
YoY Change -1.69% 2.34% -15.58%
% of Operating Profit
Other Income/Expense, Net $15.00K $16.00K $0.00
YoY Change -98.37% -100.0%
Pretax Income -$6.878M -$26.68M -$3.410M
YoY Change 101.7% 59.07% 0.89%
Income Tax $175.0K $175.0K $40.00K
% Of Pretax Income
Net Earnings -$7.053M -$26.85M -$3.450M
YoY Change 104.43% 60.91% 1.17%
Net Earnings / Revenue -55.58% -55.59% -27.23%
Basic Earnings Per Share -$1.68
Diluted Earnings Per Share -$415.4K -$1.68 -$272.7K
COMMON SHARES
Basic Shares Outstanding 16.16M shares 15.97M shares 12.65M shares
Diluted Shares Outstanding 15.97M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.44M $99.44M $57.40M
YoY Change 73.24% 73.09% -20.39%
Cash & Equivalents $99.44M $99.44M $57.45M
Short-Term Investments
Other Short-Term Assets $1.091M $3.638M $1.203M
YoY Change -9.31% -12.55% -15.7%
Inventory
Prepaid Expenses
Receivables $9.654M $9.654M $8.910M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $112.7M $112.7M $70.52M
YoY Change 59.87% 59.86% -13.21%
LONG-TERM ASSETS
Property, Plant & Equipment $4.772M $4.772M $2.102M
YoY Change 127.02% 127.24% 52.32%
Goodwill $5.506M $5.506M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $433.0K $433.0K $250.0K
YoY Change 73.2% 73.2% 43.68%
Total Long-Term Assets $10.71M $10.71M $7.858M
YoY Change 36.31% 36.27% 11.3%
TOTAL ASSETS
Total Short-Term Assets $112.7M $112.7M $70.52M
Total Long-Term Assets $10.71M $10.71M $7.858M
Total Assets $123.4M $123.4M $78.38M
YoY Change 57.51% 57.5% -11.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.492M $2.492M $3.014M
YoY Change -17.32% -17.21% 104.2%
Accrued Expenses $6.826M $6.239M $5.757M
YoY Change 18.57% 14.48% 30.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $587.0K $587.0K $300.0K
YoY Change 95.67% 89.35%
Total Short-Term Liabilities $9.318M $9.318M $8.771M
YoY Change 6.24% 6.25% 48.79%
LONG-TERM LIABILITIES
Long-Term Debt $27.48M $27.48M $26.66M
YoY Change 3.07% 3.07% 3.11%
Other Long-Term Liabilities $1.407M $1.407M $948.0K
YoY Change 48.42% 48.11% 48.59%
Total Long-Term Liabilities $28.89M $28.89M $27.61M
YoY Change 4.63% 4.62% 4.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.318M $9.318M $8.771M
Total Long-Term Liabilities $28.89M $28.89M $27.61M
Total Liabilities $38.51M $38.51M $36.54M
YoY Change 5.4% 5.39% 11.9%
SHAREHOLDERS EQUITY
Retained Earnings -$208.1M -$181.3M
YoY Change 14.81% 10.14%
Common Stock $16.00K $13.00K
YoY Change 23.08% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.94M $84.94M $41.84M
YoY Change
Total Liabilities & Shareholders Equity $123.4M $123.4M $78.38M
YoY Change 57.51% 57.5% -11.25%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$7.053M -$26.85M -$3.450M
YoY Change 104.43% 60.91% 1.17%
Depreciation, Depletion And Amortization $292.0K $900.0K $160.0K
YoY Change 82.5% 80.0% 45.45%
Cash From Operating Activities -$6.047M -$20.27M -$3.890M
YoY Change 55.45% 43.92% -1.02%
INVESTING ACTIVITIES
Capital Expenditures -$1.064M $2.370M -$10.00K
YoY Change 10540.0% 420.88% -50.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$1.064M -$2.420M -$10.00K
YoY Change 10540.0% 431.87% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $69.14M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -213.0K $64.68M -80.00K
YoY Change 166.25% -66783.51% -95.56%
NET CHANGE
Cash From Operating Activities -6.047M -$20.27M -3.890M
Cash From Investing Activities -1.064M -$2.420M -10.00K
Cash From Financing Activities -213.0K $64.68M -80.00K
Net Change In Cash -7.324M $41.99M -3.980M
YoY Change 84.02% -386.92% -30.78%
FREE CASH FLOW
Cash From Operating Activities -$6.047M -$20.27M -$3.890M
Capital Expenditures -$1.064M $2.370M -$10.00K
Free Cash Flow -$4.983M -$22.64M -$3.880M
YoY Change 28.43% 55.71% -0.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001274737
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39049
CY2021 dei Entity Registrant Name
EntityRegistrantName
EXAGEN INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0434866
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1261 Liberty Way
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Vista
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92081
CY2021 dei City Area Code
CityAreaCode
(760)
CY2021 dei Local Phone Number
LocalPhoneNumber
560-1501
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
XGN
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
158300000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16231198 shares
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99442000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57448000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9654000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8910000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3638000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4159000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
112734000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
70517000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4772000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5757000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2102000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
5506000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
5506000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
433000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000 USD
CY2021Q4 us-gaap Assets
Assets
123445000 USD
CY2020Q4 us-gaap Assets
Assets
78375000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2492000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3014000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6826000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9318000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8771000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27478000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26659000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
306000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
158000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1407000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
948000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
38509000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
36536000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16164994 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16164994 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12652308 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12652308 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
13000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
293060000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
223115000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208140000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-181289000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
84936000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41839000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123445000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78375000 USD
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48299000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41975000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20588000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16559000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44541000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37033000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7237000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3568000 USD
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
72366000 USD
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
57160000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-24067000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-15185000 USD
CY2021 us-gaap Interest Expense
InterestExpense
2625000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26851000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-16687000 USD
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.68
CY2020 us-gaap Interest Expense
InterestExpense
2565000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
984000 USD
CY2021 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-26676000 USD
CY2020 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-16766000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
175000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.68
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15972256 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15972256 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12632780 shares
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
89000 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12632780 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
55659000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
142000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2694000 USD
CY2020 exdx Stock Issued During Period Value Warrants Exercised Net
StockIssuedDuringPeriodValueWarrantsExercisedNet
18000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-16687000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41839000 USD
CY2021Q4 exdx Stock Issuance Costs
StockIssuanceCosts
4435000 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64709000 USD
CY2021 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
12775000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
12775000 USD
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
390000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4728000 USD
CY2021 exdx Stock Issued During Period Value Warrants Exercised Net
StockIssuedDuringPeriodValueWarrantsExercisedNet
32000 USD
CY2020 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-106000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26851000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
84936000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26851000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-16687000 USD
CY2021 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
948000 USD
CY2020 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
546000 USD
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
279000 USD
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
274000 USD
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
540000 USD
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
531000 USD
CY2021 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
148000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4728000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2694000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
744000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3195000 USD
CY2021 exdx Increase Decrease In Prepaid Expense And Current Other Assets
IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
-521000 USD
CY2020 exdx Increase Decrease In Prepaid Expense And Current Other Assets
IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
708000 USD
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
167000 USD
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
15000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-655000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
986000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
984000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1596000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20269000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14084000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2370000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
455000 USD
CY2021 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
50000 USD
CY2020 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2420000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-455000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
89000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000 USD
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
390000 USD
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
142000 USD
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
32000 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18000 USD
CY2021 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
525000 USD
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
249000 USD
CY2021 exdx Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan
CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
0 USD
CY2020 exdx Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan
CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
2865000 USD
CY2021 exdx Coronavirus Aid Relief And Economic Securities Cares Act Repayments Of Loan
CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan
0 USD
CY2020 exdx Coronavirus Aid Relief And Economic Securities Cares Act Repayments Of Loan
CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan
2865000 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69144000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64683000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-97000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
1300000 USD
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41994000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14636000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57548000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72184000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99542000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57548000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1815000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1758000 USD
CY2021 exdx Equipment Purchased Under Capital Lease
EquipmentPurchasedUnderCapitalLease
1111000 USD
CY2020 exdx Equipment Purchased Under Capital Lease
EquipmentPurchasedUnderCapitalLease
260000 USD
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
685000 USD
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
553000 USD
CY2021 exdx Deferred Offering Costs Included Within Current Liabilities
DeferredOfferingCostsIncludedWithinCurrentLiabilities
0 USD
CY2020 exdx Deferred Offering Costs Included Within Current Liabilities
DeferredOfferingCostsIncludedWithinCurrentLiabilities
40000 USD
CY2021 exdx Deferred Offering Costs Reclassified To Equity
DeferredOfferingCostsReclassifiedToEquity
28000 USD
CY2020 exdx Deferred Offering Costs Reclassified To Equity
DeferredOfferingCostsReclassifiedToEquity
0 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99400000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208100000 USD
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div>
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48299000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41975000 USD
CY2021 us-gaap Advertising Expense
AdvertisingExpense
1700000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99442000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57448000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
100000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
100000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99542000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57548000 USD
CY2021 us-gaap Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment
ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
700000 USD
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
800000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 exdx Share Based Compensation Arrangement By Share Based Payment Award Number Of Annual Installments
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
4 installment
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2858956 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2414228 shares
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1091000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1203000 USD
CY2021Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
49000 USD
CY2020Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
68000 USD
CY2021Q4 exdx Prepaid Maintenance And Insurance Contracts
PrepaidMaintenanceAndInsuranceContracts
2008000 USD
CY2020Q4 exdx Prepaid Maintenance And Insurance Contracts
PrepaidMaintenanceAndInsuranceContracts
2229000 USD
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
490000 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
659000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3638000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4159000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8656000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5043000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3884000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2941000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4772000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2102000 USD
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4048000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3589000 USD
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
139000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
147000 USD
CY2021Q4 exdx Accrued Purchase Goods And Services Current
AccruedPurchaseGoodsAndServicesCurrent
510000 USD
CY2020Q4 exdx Accrued Purchase Goods And Services Current
AccruedPurchaseGoodsAndServicesCurrent
311000 USD
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
180000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
221000 USD
CY2021Q4 exdx Accrued Liabilities Clinical Study Current
AccruedLiabilitiesClinicalStudyCurrent
254000 USD
CY2020Q4 exdx Accrued Liabilities Clinical Study Current
AccruedLiabilitiesClinicalStudyCurrent
228000 USD
CY2021Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
587000 USD
CY2020Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
308000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1108000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
953000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6826000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5757000 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1653000 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1686000 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2980000 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
16152000 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
14786000 USD
CY2021Q4 exdx Long Term Debt Including Undiscounted Interest
LongTermDebtIncludingUndiscountedInterest
37257000 USD
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
208000 USD
CY2021Q4 exdx Long Term Debt Undiscounted Interest Amount
LongTermDebtUndiscountedInterestAmount
9571000 USD
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
27478000 USD
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1000000.0 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
641000 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1337000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
566000 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1445000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
313000 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1489000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
66000 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1533000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
0 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1584000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
539000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
1586000 USD
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7927000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
116000 USD
CY2021Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
1470000 USD
CY2021Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
587000 USD
CY2021Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
883000 USD
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000 USD
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000 USD
CY2021Q4 exdx License Agreement Period After Commercial Sales Begin For Royalties To Be Paid
LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid
P18M
CY2021Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
3700000 USD
CY2021Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
6000000.0 USD
CY2021Q4 exdx Purchase Obligation Annual Increase In Commitment Percentage
PurchaseObligationAnnualIncreaseInCommitmentPercentage
0.15
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000 USD
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1214059 shares
CY2021 exdx Stock Issued During Period Shares Warrants Exercised Net
StockIssuedDuringPeriodSharesWarrantsExercisedNet
17719 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1975761 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.81
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6750000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
229850 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.79
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11950 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.40
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
128665 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.44
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
50666 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.18
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2014330 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.10
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5428000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2014330 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.10
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5428000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1050036 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.17
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M10D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4262000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.83
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.55
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
11.63
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.20
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
100000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4728000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2694000 USD
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5150801 shares
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
27000 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
27000 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
27000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
27000 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
137000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-117000 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
11000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
11000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
148000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-106000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
175000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.012
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.009
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.010
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.246
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.226
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22365000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17733000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1102000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
629000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1055000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
920000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1953000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1306000 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
117000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1407000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
528000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27882000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21233000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27158000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20596000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
724000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
637000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
335000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
336000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
521000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
459000 USD
CY2021Q4 exdx Deferred Tax Liabilities Fixed Assets And Intangible Assets
DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
175000 USD
CY2020Q4 exdx Deferred Tax Liabilities Fixed Assets And Intangible Assets
DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
0 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1031000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
795000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
307000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
158000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20596000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16797000 USD
CY2021 exdx Valuation Allowance Deferred Tax Asset Decrease Recorded As A Benefit To Income Tax Provision Amount
ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount
0 USD
CY2020 exdx Valuation Allowance Deferred Tax Asset Decrease Recorded As A Benefit To Income Tax Provision Amount
ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount
0 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6562000 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3799000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27158000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20596000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
89400000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
70600000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
61000000.0 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
48900000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
43500000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
45900000 USD
CY2019Q4 exdx Operating Loss Carryforwards Not Utilized
OperatingLossCarryforwardsNotUtilized
61800000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 USD
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 USD
CY2020Q4 exdx Coronavirus Aid Relief And Economic Securities Cares Act Deferred Tax Assets Valuation Allowance Income Tax Expense Benefit
CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit
-100000 USD
CY2020Q4 exdx Coronavirus Aid Relief And Economic Securities Cares Act Deferred Tax Assets Valuation Allowance Income Tax Expense Benefit
CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit
-100000 USD
CY2021Q4 exdx Coronavirus Aid Relief And Economic Securities Cares Act Deferred Tax Assets Valuation Allowance Income Tax Expense Benefit
CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowanceIncomeTaxExpenseBenefit
100000 USD
CY2020Q2 exdx Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan
CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
700000 USD
CY2020Q2 exdx Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan
CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan
700000 USD

Files In Submission

Name View Source Status
0001628280-22-006926-index-headers.html Edgar Link pending
0001628280-22-006926-index.html Edgar Link pending
0001628280-22-006926.txt Edgar Link pending
0001628280-22-006926-xbrl.zip Edgar Link pending
ex231-2021bdoconsent.htm Edgar Link pending
exdx-20211231.htm Edgar Link pending
exdx-20211231.xsd Edgar Link pending
exdx-20211231_cal.xml Edgar Link unprocessable
exdx-20211231_def.xml Edgar Link unprocessable
exdx-20211231_g1.jpg Edgar Link pending
exdx-20211231_g2.jpg Edgar Link pending
exdx-20211231_g3.jpg Edgar Link pending
exdx-20211231_g4.jpg Edgar Link pending
exdx-20211231_htm.xml Edgar Link completed
exdx-20211231_lab.xml Edgar Link unprocessable
exdx-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xgn311-123121.htm Edgar Link pending
xgn312-123121.htm Edgar Link pending
xgn321-123121.htm Edgar Link pending